A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction

Recruiting now · Phase 2

Conditions studied: Erectile Dysfunction (ED), Erectile Dysfunctions, Erectile Function

In brief

This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline. Participants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.

Key facts

Study ID

NCT07601646

Run by

Ryan Flannigan, MD

People needed

83

Starts

2026-05-01

Expected to finish

2027-05-01

Last updated by the study team

2026-05-22

Who can join

Age: 21 and older, up to 75. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Have had a confirmed clinical diagnosis of ED for more than three months based upon IIEF
• Have failed PDE5 inhibitor therapy (inability to achieve an erection with adequate rigidity to allow penetrative sex)
• Ability to take oral medication (sildenafil) and be willing to adhere to the study intervention regimen
• Engaged in heterosexual relationship with partner for a minimum of 6 months

You may not qualify if…

• History of unstable medical or psychiatric condition that, in the opinion of the principal investigator, could impact the patient's ability to complete the study investigations or protocol.
• Spinal cord injury, or penile anatomical abnormalities
• Cardiovascular conditions that prevent sexual activity (NYHA Class II or higher, any angina, or uncontrolled CHF or severe coronary artery disease)
• History of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to enrollment into the study
• Use of anti-androgens, or oral or injectable androgens
• Documented hypotension or known orthostatic hypotension
• Use of oral, topical or sublingual nitrates within 3 months prior to enrollment into the study
• Hepatic (Child-Pugh Class C) or renal failure (eGFR < 30)
• Inadequate response to intracavernosal injection therapy previously
• Peyronie's disease or Meatal stenosis

Where it is running

• Vancouver Prostate Centre — Vancouver, British Columbia, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.